2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155138
    GLS1 Inhibitor-7 98%
    GLS1 Inhibitor-7 (compound 4d) is a GLS1 inhibitor (IC50=46.7 μM), with potential anti-cancer, anti-aging and anti-obesity properties.
    GLS1 Inhibitor-7
  • HY-155241
    α-Amylase/α-Glucosidase-IN-4 98%
    α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity.
    α-Amylase/α-Glucosidase-IN-4
  • HY-155295
    Z-CITCO 2583138-04-7 98%
    Z-CITCO is the cis isomer of CITCO (HY-103244). Z-CITCO is an agonist of constitutive androstane receptor (CAR) with an EC50 value of 3.9 µM.
    Z-CITCO
  • HY-155344
    α-Glucosidase-IN-38 2991427-89-3 98%
    α-Glucosidase-IN-38 (Compound 11j) is a potent inhibitor of α-glucosidase inhibitor with IC50 of 12.44±0.38 μM.α-Glucosidase-IN-38 plays an important role in Diabetes mellitus (DM).
    α-Glucosidase-IN-38
  • HY-155372
    α-Glucosidase-IN-39 98%
    α-Glucosidase-IN-39 is a potent inhibitor of α-glucosidase enzyme with an IC50 of 869.06 ppm. α-Glucosidase-IN-39 can used in study antidiabetic.
    α-Glucosidase-IN-39
  • HY-155385
    10-Oxo-12(Z),15(Z)-octadecadienoic acid 1036406-73-1 98%
    10-Oxo-12(Z),15(Z)-octadecadienoic acid is a gut microbial fatty acid metabolite.
    10-Oxo-12(Z),15(Z)-octadecadienoic acid
  • HY-155410
    HPSE1-IN-1 2876926-29-1 98%
    HPSE1-IN-1 (compound 16) is a selective inhibitor of Heparanase-1 (HPSE1) with moderate inhibitory activity against exo-β-d-glucuronidase (GUSβ) and glucocerebrosidase (GBA).
    HPSE1-IN-1
  • HY-155411
    HPSE1-IN-2 2876926-27-9 98%
    HPSE1-IN-2 (compound 2) is a Heparanase-1 (HPSE1) inhibitor that also inhibits exo-β-d-glucuronidase (GUSβ) and glucocerebrosidase (GBA) activity.
    HPSE1-IN-2
  • HY-155473
    Phosphatidylcholine transfer protein inhibitor-2 379712-59-1 98.14%
    Phosphatidylcholine transfer protein inhibitor-2 (answer 41) is a inhibitor of phosphatidylcholine transfer protein.
    Phosphatidylcholine transfer protein inhibitor-2
  • HY-155553
    GPR119 agonist 2 1384951-03-4 98%
    GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes.
    GPR119 agonist 2
  • HY-155597
    h-NTPDase8-IN-1 716358-51-9 98%
    h-NTPDase8-IN-1 (compound 2d) is a sulfamoyl-benzamides based and selective inhibitor for h-NTPDases8 (IC50=0.28 μM). h-NTPDases8 is involved in a variety of physiological and pathological functions，such as thrombosis，diabetes，inflammation，and cancer.
    h-NTPDase8-IN-1
  • HY-155668
    HMG-CoA Reductase-IN-1 98%
    HMG-CoA Reductase-IN-1 is a HMG-CoA reductase inhibitor. HMG-CoA Reductase-IN-1has high HMGR inhibitory activity and OATP1B1 affinity with pIC50 and pKm values of 8.54 and 1.98, respectively. HMG-CoA Reductase-IN-1 can be used for the research of hypercholesterolemia.
    HMG-CoA Reductase-IN-1
  • HY-155961
    Antidiabetic agent 2 3052242-32-4 98%
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels.
    Antidiabetic agent 2
  • HY-155967
    CB1R/AMPK modulator 1 2711012-08-5 98%
    CB1R/AMPK modulator 1 (Compound 38-S) is an orally active CB1R/AMPK modulator, with an Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. CB1R/AMPK modulator 1 activates AMPK. CB1R/AMPK modulator 1 reduces food intake and body weight, and improves glucose tolerance and insulin sensitivity.
    CB1R/AMPK modulator 1
  • HY-156020
    Glucocerebrosidase-IN-2 851185-20-1 98%
    Glucocerebrosidase-IN-2 (compound 12) is a quinazoline analogue and an inhibitor of glucocerebrosidase (GC). Glucocerebrosidase-IN-2 has the potential to improve GC translocation to lysosomes in Gaucher disease patient-derived cells (mostly carrying the N370S mutation). Glucocerebrosidase-IN-2 inhibits the hydrolysis of 4-methylumbelliferone β-D-glucopyranoside (4MU) and fluorescent glycosylceramide (FlourGC) in N370S mutant tissues with an AC50 of 25.29 μM.
    Glucocerebrosidase-IN-2
  • HY-156059
    NEP28 1254176-87-8
    NEP28 is a selective androgen receptor modulator with an EC50 of 2.90 nM in 22RV1 cells. NEP28 increases the activity of Aβ-degrading enzyme neprilysin. NEP28 is efficacious in muscle and brain without serious side effects on prostate in rats. NEP28 can be used for osteoporosis, sarcopenia, and Alzheimer's disease research.
    NEP28
  • HY-156065
    S217879 2700303-28-0 98%
    S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis.
    S217879
  • HY-156078
    α-Glucosidase-IN-32 98%
    α-Glucosidase-IN-32 (compound f26) is a reversible, noncompetitive and orally active α-glucosidase inhibitor with an IC50 value of 3.07 μM. α-Glucosidase-IN-32 complex with α-glucosidase through hydrogen bonds and hydrophobic interactions, led to changes in the conformation and secondary strictures of α-glucosidase and further the inhibition of the enzymatic activity. α-Glucosidase-IN-32 can be used for diabetic disease research.
    α-Glucosidase-IN-32
  • HY-156081
    Nrf2 activator-9 98%
    Nrf2 activator-9 (compound D-36) is an Nrf2 activator that inhibits oxidized low-density lipoprotein (oxLDL) and high glucose (HG)-induced apoptosis in HUVEC cells. Nrf2 activator-9 inhibits oxLDL and HG-induced vascular endothelial cell (VEC) injury and can effectively prevent and treat atherosclerosis.
    Nrf2 activator-9
  • HY-156093
    TPH1-IN-1 3040015-86-6 98%
    TPH1-IN-1 (compound 40) is a xanthine derivative and an inhibitor of tryptophan hydroxylase TPH1 (IC50: 110.1 nM). TPH1-IN-1 has good in vitro activity and liver microsome stability, and effectively inhibits adipocyte differentiation of T3-L1 cells.
    TPH1-IN-1
Cat. No. Product Name / Synonyms Application Reactivity